# Her2-positive Lung Cancer Treated With Dedicated Drug

> **NCT03845270** · PHASE2 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 46 (actual)

## Conditions studied

- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer Stage III
- HER2 Gene Mutation

## Interventions

- **DRUG:** pertuzumab + trastuzumab + docetaxel

## Key facts

- **NCT ID:** NCT03845270
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-17
- **Primary completion:** 2021-02-01
- **Final completion:** 2023-12-18
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03845270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03845270, "Her2-positive Lung Cancer Treated With Dedicated Drug". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03845270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*